Background We have developed a novel compound from acetylsalicylic acid (ASA) and 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris) precursors with ASA-like anti-inflammatory efficacy and reduced the mucosa-damaging side-effects. Our aim was to examine local and remote consequences of ASA-Tris administration in 2-,4-,6-trinitrobenzene-sulfonic acid (TNBS)-induced colitis as compared to ASA or mesalamine (5-aminosalicylate) treatment. Methods Sprague-Dawley rats were randomized to five groups (n = 6, each), and TNBS enemas were performed. Group 1 was the negative control; group 2 was the untreated colitis group. 12 hour after colitis induction repeated doses of ASA, ASA-Tris (both 0.55 mmol/kg) and mesalamine (0.77 mmol/kg) were given 3 times daily for 3 days to groups 3-5. On day 3 of colitis, the in vivo histology of the colon and stomach was investigated. Tissue xanthine-oxidoreductase, myeloperoxidase, nitrite/ nitrate changes, and circulating TNF-alpha levels were measured. In addition, liver mitochondria were examined with high-resolution respirometry to analyze alterations in the electron transport chain.
Inflammatory bowel diseases (IBDs) are accompanied by local and systemic immune responses with the recruitment of effector cells and the release of humoral mediators, which collectively enhance the breakdown of the mucosal barrier (Appleyard et al. 2002; Hatoum et al. 2003; Hatoum and Binion 2005) . Indeed, current treatment strategies of IBD are based on immune modulators, anti-inflammatory compounds and the use of anti-cytokine agents, including tumour necrosis factor-a (TNF-a) blockers (Rutgeerts et al. 2004) . Non-steroidal anti-inflammatory drugs (NSAIDs) are also considered as useful additional medication for IBD patients, mostly with extraintestinal, musculoskeletal disorders (Jose and Heyman 2008) . However, each of these therapies can cause potentially severe side effects, and questions on their tolerability have also been emerged (Blackburn et al. 2002; Donihi et al. 2006; Hasselgren et al. 2010) . NSAID administration is no exception; and the increased risk of gastrointestinal (GI) mucosal injuries, ulcerative damages after regular, long-term use is well recognized.
Earlier studies from our laboratory demonstrated that acetylsalicylic acid (ASA) chemically combined with trishydroxymethyl-aminomethane (Tris) exhibits strong bioactivity against inflammation and has a less harmful effect on the gastric mucosa than the original ASA (Varga et al. 2016) . The administration of the novel 2-(acetyloxy)-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-benzamide (ASA-Tris) compound resulted in sustained and prolonged anti-inflammation and anti-nociception effects in carrageenan-induced arthritis in rats and simultaneously prevented the injury of microvascular structures and the accumulation of polymorphonuclear leukocytes within the gastric tissues (Varga et al. 2016) . Using this as a basis, we hypothesized that this approach might provide a therapeutic benefit in experimental colitis as well. Hence, our first goal was to characterize the local and distant effects of ASA-Tris and ASA treatments in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colon damage, a commonly used murine IBD model in preclinical efficacy studies. To draw meaningful conclusions, positive controls were incorporated into the protocol. Mesalamine, a 5-aminosalicylic acid compound (5-aminosalicylate, or 5-ASA) (Managlia et al. 2013) , is often used as the first line of therapy of IBD (Braus and Elliott 2009 ). It acts locally in the bowel and as a result it has relatively few systemic side effects (Bickston and Cominelli 2003) . With this in mind, the local, colonic and distant, gastric effects of mesalamine treatment were also investigated and compared to assess the therapeutic potential of ASA-Tris.
The pathway by which intestinal tissue damage evolves in IBD is still not known, but it appears that a perturbed mitochondrial oxidative phosphorylation (OxPhos) is an important contributing factor in the pathomechanism of the disease. In IBD patients the colonic mucosa is often characterized by lower adenosine triphosphate (ATP) levels, and significantly decreased mitochondrial Complex II activity was also detected (Kameyama et al. 1984; Santhanam et al. 2012) . It was also shown that TNBS administration causes significant structural damage of epithelial mitochondria with swelling and disruption of the inner membrane (Bou-Fersen et al. 2008) , and a reduced Complex II activity was also demonstrated in dextran sodium sulphate-induced experimental colitis as well (Santhanam et al. 2012) .
Interestingly, in addition to other cellular effects, both ASA and aminosalicylates may influence mitochondrial Oxphos and hence modify the energetics of enterocytes (Madesh and Balasubramanian 1998) . Along these lines, we examined the second hypothesis that ASA-Tris may influence GI inflammation by alleviating mitochondrial dysfunction. To this end, we designed in vitro tests using high resolution respirometry to analyze the effects of ASA and ASA-Tris on mitochondrial function.
Materials and methods
The synthesis of the compound and the supporting 1 H NMR and HPLC studies were carried out in the Department of Medical Chemistry, University of Szeged, the procedure and the structural characterization were described in details in a previous communication (Varga et al. 2016) (Fig. 1) .
Animals
The experimental protocols were carried out in accordance with EU directive 2010/63 for the protection of animals used for scientific purposes and they were approved by the National Scientific Ethical Committee on Animal Experimentation (National Competent Authority) with license number V./146/2013. This study also complied with the criteria of the US National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
The experiments were performed in two series on a total of 45 male Sprague-Dawley rats (average weight 200 g ± 10 g), housed in plastic cages in a thermoneutral environment (21 ± 2°C) with a 12-h dark-light cycle. The animals were kept on normal laboratory chow and then fed with a carbohydrate-rich diet (bread rolls) for 3 days prior to the experiments.
In vivo study to determine the anti-inflammatory effects of ASA and ASA-Tris treatments in experimental colitis
Induction of colitis
The animals were deprived of food, but not water, for 12 h prior to the enemas. Colonic inflammation was induced by the intracolonic (ic) administration of TNBS (40 mg/kg in 0.25 ml of 25% ethanol) through an 8 cm-long soft plastic catheter under transient light inhalation anesthesia (Morris et al. 1989) . In sham-operated groups, only the vehicle for TNBS was administered. The animals were then returned to their cages and were fed ad libitum with standard laboratory chow.
In vivo detection of tissue damage
The extent of the damage of the gastric and colonic mucosa was evaluated by means of fluorescence confocal laser scanning endomicroscopy (CLSEM, Five1, Optiscan Pty. Ltd., Melbourne, Victoria, Australia) developed for in vivo histology. The analysis was performed twice, independently by two investigators (GV and NL). The mucosal surface of the stomach or distal colon (8 cm proximal to the anus) was surgically exposed and laid flat for examination. The microvascular structure was recorded after the iv administration of 0.3 ml of fluorescein isothiocyanatedextran (FITC-dextran, 150 kDa, 20 mg/ml solution dissolved in saline, Sigma-Aldrich Inc, St. Louis, MO, USA). The objective of the device was placed onto the mucosal surface of the descending colon, and confocal imaging was performed 5 min after dye administration (1 scan/image, 1024 9 512 pixels and 475 9 475 lm per image). The changes in the mucosal architecture were examined following the topical application of the fluorescent dye acridine orange (Sigma-Aldrich Inc, St. Louis, MO, USA). Afterwards, the surplus dye was washed off the mucosal surface of the colon with saline 2 min before imaging.
Non-overlapping fields of gastric and colon tissues in colitis group were compared with the samples of ASA-, ASA-Tris, and mesalamine-treated or control groups using a semiquantitative scoring system developed for in vivo histology, as described previously (Kovács et al. 2012; Varga et al. 2016 ).
Preparation of tissue biopsies
Tissue biopsies kept on ice were homogenized in a phosphate buffer (pH 7.4) containing 50 mM of Tris-HCl (Reanal, Budapest, Hungary), 0.1 mM of EDTA, 0.5 mM of dithiotreitol, 1 mM of phenylmethylsulfonyl fluoride, 10 lg/ml of soybean trypsin inhibitor and 10 lg/ml of leupeptin (Sigma-Aldrich GmbH, Germany). The homogenate was centrifuged at 4°C for 20 min at 24,000g and the supernatant was loaded into centrifugal concentrator tubes (Amicon Centricon-100; 100,000 MW cut-off ultrafilter). The activity of xanthine oxidoreductase (XOR) was determined in the ultrafiltered supernatant, while that of myeloperoxidase (MPO) was measured on the pellet of the homogenate.
Tissue MPO enzyme activity
The activity of MPO as a marker of tissue leukocyte infiltration was measured on the pellet of the homogenate (Kuebler et al. 1996) . Briefly, the pellet was resuspended in a K 3 PO 4 buffer (0.05 M; pH 6.0) containing 0.5% of hexa-1,6-bis-decyltriethylammonium bromide. After three repeated freeze-thaw procedures, the material was centrifuged at 4°C for 20 min at 24,000g and the supernatant was used for MPO determination. Next, 0.15 ml of 3,3 0 ,5,5 0 -tetramethylbenzidine (dissolved in DMSO; 1.6 mM) and 0.75 ml of hydrogen peroxide (dissolved in K 3 PO 4 buffer; 0.6 mM) were added to 0.1 ml of the sample. The reaction led to the hydrogen peroxide-dependent oxidation of tetramethylbenzidine, which could be detected spectrophotometrically at 450 nm (UV-1601 spectrophotometer; Shimadzu, Kyoto, Japan). MPO activities were measured at 37°C; then the reaction was halted after 5 min by the addition of 0.2 ml of H 2 SO 4 (2 M). The data were expressed in terms of the protein content.
XOR activity
XOR activity was determined in the ultrafiltered, concentrated supernatant by a fluorometric kinetic assay based on the conversion of pterine to isoxanthopterine in the presence (total XOR) or absence (xanthine oxidase activity) of the electron acceptor methylene blue (Beckman et al. 1989 ).
Measurement of tissue NO products
Nitrite and nitrate (NO x ), stable end-products of NO, were determined in the gastric and intestinal homogenates by the Griess reaction. This assay depends on the enzymatic reduction of nitrate to nitrite, which is then converted into a colored azo compound that is detected spectrophotometrically at 540 nm. The total NO x was then calculated and expressed in terms of lmol/(mg protein) (Moshage et al. 1995 ).
Plasma TNF-a level measurements
Blood samples (0.5 ml) taken from the inferior caval vein were collected into precooled, heparizined (100 U/ml) polypropylene tubes and then centrifuged at 1000g at 4°C for 30 min and stored at -70°C until assay. The plasma TNF-a concentration was determined in duplicate by means of a commercially available enzyme-linked immunosorbent assay (Quantikine ultrasensitive ELISA kit for rat TNF-a; Biomedica Hungaria Kft, Budapest, Hungary). The minimum detectable level was less than 5 pg/ ml, and the interassay and intra-assay coefficients of variation were less than 10%.
Experimental protocol and surgical preparation
In control group 1 (n = 6), the animals received enemas with a total volume of 0.25 ml containing 25% of ethanol (the solvent for TNBS). In groups 2, 3, 4 and 5 (n = 6, each) colitis was induced with a TNBS enema (40 mg/kg). In groups 3, 4 and 5 repeated doses of ASA (Col ? ASA; 0.55 mmol/kg (100 mg/kg), in a volume of 10 ml/kg; three times per day for 3 days), ASA-Tris conjugate (Col ? ASA-Tris; 0.55 mmol/kg (161 mg/kg), in a volume of 10 ml/kg; three times per day for 3 days), or mesalamine (Col ? Mes; 0.77 mmol/kg (118 mg/kg), in a volume of 10 ml/kg; three times per day for 3 days) were gavaged to the animals 12 h after colitis induction. In a previous study, the same acute, single-dose ASA-Tris administrations reduced inflammatory pain as effectively as ASA in equimolar doses (Varga et al. 2016) . The animals in the control and the non-treated colitis groups were gavaged with the solvent for ASA (10 ml/kg buffered 0.11 M of potassium hydroxide).
On day 3, 2 h after the last treatment, the animals were anesthetized and surgery was performed. For instrumentation purposes, the animals were placed in a supine position on heating pads. The trachea and the right jugular vein were cannulated and after a midline abdominal incision, the lumen of the stomach and the distal colon was exposed; then the mucosa was rinsed with saline to remove bowel or gastric contents. In each group, an in vivo histology of the colonic and gastric mucosa was performed by CLSEM to examine the changes in microvasculature and superficial morphology. At the end of the experiments, full-thickness tissue samples were taken to measure mucosal biochemical changes, and venous blood samples were taken to determine the plasma TNF-a level.
The in vivo experimental protocol used to determine the mitochondrial effects of ASA and ASA-Tris treatments Fifteen animals were randomly allocated to 3 groups (n = 5, each). Group 1 served as the vehicle-treated control (10 ml/kg buffered 0.11 M of potassium hydroxide was given orally three times per day for three consecutive days). In group 2, ASA solution [0.55 mmol/kg (100 mg/ kg), in a volume of 10 ml/kg; three times per day for 3 days] was gavaged via a flexible oesophageal tube to the animals. Group 3 was treated with the ASA-Tris conjugate in equimolar doses to ASA [0.55 mmol/kg (161 mg/kg), in a volume of 10 ml/kg; three times per day for 3 days]. After the treatments, the animals were then returned to their cages and were fed ad libitum with a carbohydraterich diet. On day 3, 2 h after the last treatments, the animals were anaesthetized with sodium pentobarbital (50 mg/kg ip) and in each group, liver samples were taken for an analysis of the mitochondrial respiration.
Measurements of mitochondrial function
Changes in respiratory activity and reactive oxygen species (ROS)-producing capacity of rat-liver mitochondria were determined with high-resolution respirometry (Oxygraph2k respirometer, Oroboros Instruments, Innsbruck, Austria). Tissue samples taken from the left liver lobes of anesthetized animals (n = 5, in each group) were homogenized with a glass Potter homogenizer, followed by centrifugation in an isotonic sucrose medium (300 mM sucrose, 0.2 mM EDTA and 10 mM HEPES, adjusted to pH 7.4 with KOH at 4°C) using the method of Gnaiger et al. (2000) . After the last centrifugation, mitochondrial pellets were resuspended in a 3 ml MitOx2 (mitochondrial respiration) medium and utilized for high-resolution respirometry.
The respiratory activity of isolated mitochondria
For the respirometric analysis of the mitochondrial oxidative phosphorylation (OxPhos) system, we applied the Substrate-Uncoupler-Inhibitor Titration (SUIT) protocol. The rate of Complex I-linked respiration was determined after the addition of 2 mM of malate and 10 mM of glutamate (state II respiration) and 2.5 mM of ADP (state III respiration). 10 mM of succinate was added to determine the Complex I and Complex II state III respiration, along with 0.5 lM of rotenone for Complex II-linked respiration, 2.5 lM of antimycin A (Complex III inhibitor) and 2 mM of ascorbate and 20 lM of N,N,N,N-tetramethyl-pphenylenediamine (TMPD) for Complex IV-linked respiration. Lastly, 5 lM of Complex IV inhibitor sodium-azid was added to the medium. The DatLab software (Oroboros Instruments) was used for the data analysis, and the respirometry data were normalized to the mitochondrial biomass (Hütter et al. 2007 ).
Mitochondrial ROS production
ROS generation (i.e. superoxide anion radical production) was estimated from hydrogen peroxide (H 2 O 2 ) release and monitored fluorimetrically via the Amplex Red/horseradish peroxidase system, whereby Amplex Red (non-fluorescent) becomes oxidized to Resorufin. The calibration of H 2 O 2 production was performed by the addition of known amounts of H 2 O 2 . With this protocol, rat-liver mitochondria were incubated with oxidizing Complex II-substrate succinate in the presence of respiratory chain inhibitors (rotenone and antimycin-A). Also using this protocol, the H 2 O 2 production at Complex I was estimated based on the reverse electron flux (RET) from Complex II.
Statistical analysis
Data analysis was performed with a statistical software package (SigmaStat for Windows, Jandel Scientific, Erkrath, Germany). Changes in variables within and between groups were analyzed using two-way repeated measures ANOVA, followed by the Bonferroni test in those cases of mitochondrial respiratory function, and H 2 O 2 production. A Friedman repeated measures analysis of variance on ranks was applied within groups in the colitis study. Timedependent differences from the baseline for each group were assessed using Dunn's method. Differences between groups were analysed with a Kruskal-Wallis one-way analysis of variance on ranks, followed by Dunn's method for a pairwise multiple comparison. In the figures, median values and 75th and 25th percentiles are given; p values \0.05 were considered significant.
Results

Colitis study
The severity of colitis was estimated with macroscopic changes in the stool and the measurement of body weight. TNBS induction was accompanied by diarrhoea and the appearance of blood in the faeces in contrast with that in the control group. On day 3 of TNBS colitis the animals exhibited a significant weight loss relative to the baseline body weight (day 0) and the average weight in control group. ASA-Tris and mesalamine treatments prevented the weight loss relative to that in the control groups (Fig. 2) .
In vivo detection of mucosal injury in the colon
In the vehicle-treated controls, the network of capillaries exhibited a honeycomb pattern and the luminal openings of the crypts were covered with a continuous layer of epithelial cells, which appeared as black holes that opened onto the surface of the mucosa (Fig. 3a, f ; Table 1 ). The tissue damage was evident after TNBS enemas. Fluorescent dye leakage with edema formation was present 3 days after TNBS treatments (Fig. 3b) and the complete loss of the epithelium was commonly observed (Fig. 3g, Table 1 ). ASA treatment moderated the severity of injury, but these changes were still apparent (Figs. 3c, 5h ; Table 1 ). ASATris ( Fig. 3d, i ; Table 1 ) and mesalamine ( Fig. 3e, j ; Table 1 ) treatments prevented the structural changes in the microvasculature and the loss of epithelium of the inflamed colonic mucosa.
In vivo detection of mucosal injury in the stomach
In the control group, the network of capillaries and gastric mucosal epithelium exhibited a normal pattern (M = 0; p25 = 0; p75 = 0.3; Table 2 ). The TNBS enema did not cause gastritis (M = 0.6; p25 = 0; p75 = 1.7), while significant tissue damage was present in the ASA-treated colitis group in contrast with the control group. The capillary network was injured and fluorescent dye leakage suggested increased endothelial permeability which resulted in edema formation and structural tissue damage (M = 5.3; p25 = 4.8; p75 = 5.7). In the ASA-Tris-treated group this damage was not present (M = 0; p25 = 0; p75 = 0.5; Table 2 ) and also in the case of mesalaminetreated colitis groups the normal capillary and mucosal patterns were observed (M = 0; p25 = 0; p75 = 0.4; Table 2 ).
MPO and XOR activities and tissue NO x level in the colon
The activity of XOR is one of the most important sources of reactive oxygen species in the GI tissues that can greatly increase tissue damage. Another important effect of the ROS produced by the XOR system is the activation and local accumulation of neutrophil leukocytes, which can be investigated by the measurement of tissue MPO enzyme activity. Activated neutrophils can contribute to the NO production along with the endothelium. The increased level of NO and ROS production can further enhance tissue damage with the formation of peroxynitrite, a highly oxidative agent with relatively long biological half-life. The NO x level refers directly to the intensity of NO production. The MPO and XOR activities and NO x levels in the distal colon significantly increased 3 days after colitis compared to the controls. Two hour after the last ASAtreatment, the colonic MPO activity was decreased e Normal mucosal vasculature after 3 days of colitis and mesalamine treatment. Lower panel CLSEM after topical administration of acriflavine: f the normal structure of the mucosa in the control group. g The total loss of epithelium on the surface on day 3 of colitis. h The enlarged spaces between the glands on day 3 of colitis and ASA treatment. i The normal structure of the mucosa on day 3 of colitis and ASA-Tris treatment. j The normal structure of the mucosa on day 3 of colitis and mesalamine treatment Table 1 The effects of ASA, ASA-Tris or mesalamine treatments on changes in mucosal structure of the colon and TNF-alpha levels (pmol/ml) significantly relative to the colitis group. The ASA-Tris and mesalamine treatments resulted in a significant decrease in MPO activity as compared with that in the colitis or ASAtreated colitis groups (Fig. 4a) . ASA treatment did not influence the elevated XOR activity, but both ASA-Tris and mesalamine treatment effectively reduced the activation of XOR (Fig. 4b) .
In the ASA-treated colitis group, the elevation of NO x was significantly higher in comparison with the control group. Both ASA-Tris and mesalamine treatments decreased the NO x elevation, unlike that in the non-treated colitis or ASA-treated colitis groups (Fig. 4c) .
MPO and XOR enzyme activity and tissue NO x level in the stomach
On day 3 of colitis, the gastric MPO and XOR activities were significantly increased in contrast to those in the control group, while the NO x level did not change in the gastric tissue.
Two hour after the last ASA treatment, the MPO activity remained significantly elevated relative to that in the control group. The ASA-Tris and mesalamine treatments reduced the elevation in the MPO activity in the stomach as compared to that in the colitis or ASA-treated colitis groups (Table 2) .
ASA treatment did not influence the increased XOR enzyme activity, while ASA-Tris and mesalamine treatment prevented the elevated activation of XOR enzyme (Table 2 ).
In the ASA-treated colitis group, the elevation of NO x was significantly higher than that in the control group. ASA-Tris and mesalamine treatments did not increase NO x , in contrast with that in the ASA-treated colitis group (Table 2) .
Changes in plasma TNF-a level
The source of TNF-a may be the lymphocytes or activated neutrophil leukocytes. It can further enhance ROS production and the release of other proinflammatory cytokines (Neurath et al. 1997) . The importance of TNF-a was described in the pathogenesis of IBDs and it is a significant target of the biological therapy of IBDs (Ferrante et al. 2007; Rutgeerts et al. 2004 ). The plasma level of TNF-a significantly increased after colitis induction as compared with that in the control group. The plasma level of TNF-a in the ASA-treated group with that in decreased relative to the colitis group. ASA-Tris and mesalamin treatment significantly decreased the plasma TNF-a level, in contrast to that in the non-treated colitis and ASA-treated colitis groups (Table 1) .
Functional mitochondrial changes
Respiratory activity of mitochondria
Basal mitochondrial respiration was induced by adding substrates of Complex I (Fig. 5) . The saturating concentration of ADP resulted in a twofold increase in Complex I-linked respiration. After a stable signal had been attained, Complex II-dependent respiration was stimulated by adding succinate, which caused a further 1.5-fold increase in all the groups. Complex I was then inhibited with rotenone to assess Complex II-linked respiration. There was a tendency in the ASA group to display lower respiratory values in Complex I-and II-dependent oxygen consumption, but these differences were statistically not significant among the groups.
After Complex III inhibition with antimycin-A, the residual O 2 consumption was identical in all the groups. However, when ascorbate and TMPD were added to the medium, Complex IV-linked respiration significantly decreased in the ASA group as compared with that in the control and ASA-Tris groups. Next, the inhibition of Complex IV by adding sodium-azide resulted in significantly lower residual respiratory flux in the ASA-treated group, but in the ASA-Tris group (Fig. 5 ) this was restored to the level of the control group. 
ROS production of mitochondria
In the control group, H 2 O 2 generation with succinate as the sole substrate was partly inhibited by rotenone; however, the subsequent addition of antimycin-A resulted in a fourfold increase in H 2 O 2 formation. From these results, it seems that in this set-up H 2 O 2 production was linked to the leakage of electrons at Complex I and Complex III, but Complex III-linked events were predominant. ASA and ASA-Tris administrations did not influence mitochondrial H 2 O 2 production significantly (Fig. 6 ).
Discussion
The lack of understanding of the aetiology and pathomechanism of IBD makes it essential to search for new treatment modalities that can potentially modulate the outcome of these diseases. Currently, the role of NSAIDs in IBD therapy is still uncertain as cyclooxygenase inhibitors can either aggravate or ameliorate the activity of the disease (Takeuchi et al. 2006; Ding et al. 2014) . In addition, hemorrhagic GI side effects can also often hinder the use of these compounds. Despite this, NSAIDs are viewed as helpful additional medication for IBD patients, especially with musculoskeletal disorders such as peripheral arthritis or ankylosing spondylitis (Jose and Heyman 2008) .
The main goal of this study was to test the therapeutic potential of ASA-Tris, mesalamine and ASA treatments in TNBS colitis, a standardized stress induction method where various degrees of mucosal damage are expected in different regions of the GI tract. In our protocol, a TNBS enema caused a significant weight loss and severe mucosal damage in the colon, increased local inflammatory enzyme activity and elevated the plasma TNF-a level. The degree of mucosal injury in the colon and the stomach was observed in parallel by intravital CLSEM imaging, and the in vivo histology confirmed a severe loss of the epithelial In IBD, the intramural perfusion of the colon is usually deranged (Laroux and Grisham 2001) and the microcirculatory impairment is accompanied by increased cell-cell interactions (Granger 1999) . The activation of ROS-generating enzymes, such as XOR, leads to an increased ROS formation and the functional endothelial disorder shifts the balance between the vasoconstrictor and vasodilator agents (Palmer et al. 1987; Masaki 1989; Hatoum et al. 2003) . The inflow of polymorphonuclear (PMN) leukocytes in the villus microcirculation provokes further microvascular damage (Granger and Kubes 1994) and these changes together increase the capillary permeability and result in edema formation (Granger et al. 1988) . These characteristic signs were all detected in the present study; moreover, the potentially detrimental microvascular alterations were accompanied by enhanced XOR activity and elevated tissue MPO levels. Furthermore, these changes were accompanied by increased local NO x concentrations, providing indirect evidence for evolving oxido-nitrosative stress in the intestinal tissue. Besides this, the increased circulating plasma TNF-a concentrations demonstrated the spreading of inflammatory signals and the systemic aspect of a local insult. In spite of this, the induction of colitis did not result in remote injury in the stomach; an in vivo histology demonstrated that the normal mucosal characteristics and also normal inflammatory enzyme activities were present in the gastric tissue.
Our previous cross-sectional study demonstrated that biologically active product can be synthesized from ASA and Tris precursors with a much less damaging effect on the gastric mucosa than that with the original ASA (Varga et al. 2016) . In the present study we have extended the scope of these investigations, and the in vivo histology provided evidence that ASA treatment does not entirely prevent the evolution of TNBS-induced injury in the large intestine. The capillary permeability remained higher and, simultaneously, increased XOR activity and NO x levels were detected. ASA-Tris, however, effectively reduced the weight loss, decreased the level of inflammatory markers in the colon, and mucosal destruction was also diminished. The in vivo microscopic observation of the colonic mucosal surface provided evidence for an intact microvascular structure, and the effects of the ASA-Tris conjugate were similar to the efficacy of mesalamine in the colon on the third day of colitis.
The effects of the treatments were compared and evaluated on the gastric mucosa as well. Mesalamine and ASATris administration did not cause gastric damage and they did not change the level of inflammatory markers in the stomach, but the administration of ASA elevated the oxidative and nitrosative stress markers; and besides this, tissue injury was observed. The ASA therapy-induced damage of the gastric mucosal surface was characterized by the loss of epithelium and accompanied by visible signs of capillary injury.
The exact molecular background governing the process of IBD is still poorly understood, but the overproduction of inflammatory cytokines, including TNF-a is viewed as fundamental. TNF-a is thought to be largely responsible for the spreading of local reactions to remote organs, and the TNF-a blockade has the theoretical advantage of abrogating the systemic inflammatory response at an earlier stage and in a specific fashion. In this study the TNBS colitis elevated the plasma TNF-a level significantly and, once again this increase was moderated by ASA-Tris treatment, which is as efficient as mesalamine treatment.
The precise mechanism of action of ASA-Tris is not known for certain today. Tris is commonly used as a component of buffer solutions, which is effective between pH ranges 7.07 and 9.07, and a preferred alternative in patients with mixed acidosis (Kallet et al. 2000; Hoste et al. 2005) . Apart from its influence on acidemia, Tris may inhibit enzyme activities, such as aminopeptidases and alpha-amylases (Desmarais et al. 2002; Ghalanbor et al. 2008) . Of note, Tris is an important constituent of the NSAID ketorolac tromethamine salt (ketorolac and Tris 1:1) because it enhances the solubility and bioavailability (Mroszczak et al. 1987) . Based on this background, it seemed plausible that a new drug synthesized from ASA and Tris precursors might favourably affect the degree of ASA-induced mucosal damage. In our previous study where the effects of ASA-mono-hydroxymethyl-aminomethane, ASA-bis-hydroxymethyl-aminomethane and ASA-Tris derivatives were compared, the degree of efficacy of these compounds was found to be proportional to the number of hydroxy groups (Varga et al. 2016 ). This suggests that there is a redox control mechanism present, where the alcoholic moiety of ASA-Tris may play an active role in this process and this presumably leads to a reduction in membrane damage.
As we mentioned above, the pathways leading to mucosal destruction are still not well understood, but IBD is characterized by an energy deficiency state of the colonic epithelium (Kameyama et al. 1984) . It was also shown that ASA administration may also inhibit mitochondrial respiration and the production of ATP in a concentrationdependent manner (Spenney and Bhown 1977) . Previously, it was also demonstrated that cyclooxygenase inhibition opens mitochondrial permeability transition pores, which is responsible for cytochrome c release, a marker of mitochondrial inner membrane damage (Gugliucci et al. 2002 ). In the current study, ASA treatment led to mitochondrial dysfunction involving depressed mitochondrial electron transport and lower OxPhos capacity. The decreased electron flux was accompanied by the inhibition of the activities of respiratory chain enzymes, especially cytochrome c oxidase (Complex IV). The in vitro experimental data demonstrated the direct effects of ASA-Tris on isolated liver mitochondria. The respiratory complex-specific H 2 O 2 production was not affected by the compound, but the ASA-Tris conjugate reduced the disturbances associated with electron transport and increased the efficacy of oxygen consumption. Our results, therefore, suggest that ASA-Tris is not a radical scavenger directly; rather the favourable effects are probably linked to its protective potential against oxidative biomembrane damage. This view is supported by our previous in vivo study, which showed that ASA increased gastric malondialdehyde levels in rats, which demonstrates the increased level of membrane lipid peroxidation. What is more, ASA caused an inhibition of the function of the mitochondrial respiratory chain, while the same phenomenon was not observed in the case of the ASA-Tris conjugate (Varga et al. 2016) .
In summary, our study has revealed that the ASA-Tris conjugate significantly decreased the degree of inflammatory damage in the large intestine by targeting local potentially destructive changes without inducing significant side-effects on the gastric mucosa. The investigations explain the anti-inflammatory action at the mitochondrial level and provide a mechanistic basis for the observations. The study has certain limitations, as well. TNBS colitis is accompanied by acute, erosive epithelial injuries, and therefore, chronic models that are more dependent upon the adaptive immune system are clearly needed to explain how the various pharmacologic manipulations affect the mucosal barrier repair in addition to the inflammatory response. Nevertheless, our findings suggest that ASA-Tris might be a promising alternative to NSAID therapy and may, therefore, be a good option for future therapeutic investigations of IBD.
